UniQure Faces Setback as U.S. Regulators Demand Additional Study for Huntington's Gene Therapy

UniQure's stock experienced a significant drop following the announcement by U.S. regulators that the company must conduct an additional study of its gene therapy for Huntington's disease prior to approval. Bloomberg posted on X, highlighting this as the latest instance of the Trump administration delaying treatment for rare diseases. The decision marks a setback for UniQure, which has been working on innovative solutions for Huntington's disease, a genetic disorder that affects the brain. The requirement for further research underscores the regulatory challenges faced by companies developing treatments for rare conditions. UniQure's gene therapy aims to address the underlying causes of Huntington's disease, offering hope for patients and families affected by the condition. However, the need for additional studies may prolong the timeline for bringing this therapy to market, impacting both the company and those awaiting new treatment options.